p504S Antibody / Prostate Cancer Marker Antibody [clone 13H4] (V8770)

Description

Alpha-methylacyl-CoA racemase (AMACR) is a peroxisomal and mitochondrial metabolic enzyme involved in branched-chain fatty acid metabolism and bile acid biosynthesis. p504S Antibody / Prostate Cancer Marker Antibody recognizes AMACR, a widely studied carcinoma-associated metabolic enzyme that is frequently overexpressed in prostate adenocarcinoma and additional epithelial malignancies.

p504S antibody, also referred to as AMACR antibody and Alpha-methylacyl-CoA racemase antibody in the literature, is extensively used in prostate cancer research and diagnostic pathology applications. Clone 13H4 antibody has been cited in numerous peer-reviewed publications and is broadly recognized as a historically important p504S monoclonal antibody for investigating prostate carcinoma-associated metabolic reprogramming and epithelial tumor biology.

AMACR expression is commonly elevated in prostate adenocarcinoma relative to benign prostatic glands, contributing to the widespread use of p504S antibodies in studies examining prostate tumor differentiation and carcinoma-associated biomarker expression. In immunohistochemistry applications, AMACR typically demonstrates granular cytoplasmic staining within malignant epithelial cells, reflecting its localization to intracellular metabolic organelles including peroxisomes and mitochondria.

Beyond prostate cancer, increased AMACR expression has also been reported in colorectal carcinoma, hepatocellular carcinoma, renal tumors, and additional epithelial malignancies. The enzyme participates in lipid metabolic pathways associated with branched-chain fatty acid degradation, supporting growing interest in AMACR as a marker of tumor-associated metabolic adaptation and altered fatty acid utilization.

Western blot analysis using clone 13H4 commonly identifies AMACR near 40-42 kDa, consistent with the predicted molecular weight of the mature protein. Protein microarray analysis containing more than 19,000 full-length human proteins identified AMACR as the dominant target recognized by clone 13H4, supporting strong preferential binding to Alpha-methylacyl-CoA racemase relative to unrelated proteins on the array.

The longstanding use of p504S antibodies in cancer pathology research has contributed to the broad recognition of AMACR as a clinically relevant prostate carcinoma marker and metabolism-associated tumor biomarker. Continued interest in cancer metabolism, lipid utilization pathways, and epithelial differentiation biology further supports the utility of p504S antibodies in modern tumor biology research applications.

Together, the available western blot, immunohistochemistry, publication history, and protein array specificity data support the use of clone 13H4 for investigating AMACR expression and carcinoma-associated metabolic signaling pathways in epithelial tumor biology.

For additional AMACR and p504S research antibodies validated by protein microarray specificity analysis, western blotting, and immunohistochemistry, explore the broader AMACR Antibody page featuring clone AMACR/1864.

Application Notes

Optimal dilution of the p504S Antibody / Prostate Cancer Marker Antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

Full length human recombinant protein was used as the immunogen for the p504S antibody.

Storage

Store the p504S antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Alternate Names

p504S antibody, AMACR antibody, Alpha-methylacyl-CoA racemase antibody, prostate carcinoma marker antibody, clone 13H4 antibody